<HTML>
<head><title>8K Eastgate Biotech - 09.04.19</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:'Times New Roman'; MARGIN-TOP:0px; COLOR:#000000"> <div style=WIDTH:576px> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>UNITED STATES</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>Washington, DC 20549</b></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>FORM 8-K</b></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>CURRENT REPORT</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>Pursuant to Section 13 or 15(d) of the</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>Securities Exchange Act of 1934</b></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">Date of report (Date of earliest event reported): &nbsp;<u>September 4, 2019</u></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">Commission File Number: &nbsp;<u>00052886</u></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:18pt; MARGIN:0px" align=center><b>EASTGATE BIOTECH CORP.</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Exact name of small business issuer as specified in its charter)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><u>Nevada</u></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(State or other jurisdiction of incorporation or organization)</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><u>87-0639378 </u></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(IRS Employer Identification No.)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px">&nbsp;&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>2203-65 Harbour Square | Toronto, Ontario | Canada M5J 2L4</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Address of principal executive offices)</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><b>(647) 692-0652</b></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Registrant's Telephone number)</p> <p style="FONT-SIZE:14.5pt; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center><u>__________________________</u></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=center>(Former Name or Former Address, if Changed Since Last Report)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; PAGE-BREAK-BEFORE:always; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="FONT-SIZE:14.5pt; FONT-FAMILY:Calibri Bold Italic,Times New Roman; MARGIN:0px">&nbsp;</p> <p style="FONT-SIZE:13pt; MARGIN:0px">[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify><b><u>Item 5.02 &nbsp;Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;</u></b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>On September 4, 2019, the Company announced the appointment of Bill Abajian as Chief Operating Officer. &nbsp;The details of his appointment are outlined in the press release attached hereto as Exhibit 10.1 originally released on September 4, 2019. </p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify><b><u>Item 9.01 &nbsp;Exhibits.</u></b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>(d) Exhibits.</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>10.1 &nbsp;Press Release of September 4, 2019</p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify><b>SIGNATURE</b></p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px" align=justify>Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style=MARGIN:0px align=justify><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:13pt; MARGIN:0px">EastGate Biotech Corp. </p> <p style="FONT-SIZE:13pt; MARGIN:0px">(Registrant)</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style="FONT-SIZE:13pt; MARGIN-BOTTOM:-2px; WIDTH:288px; MARGIN-TOP:0px; FLOAT:left">Date: &nbsp;September 13, 2019 </p> <p style="FONT-SIZE:13pt; MARGIN:0px; TEXT-INDENT:-2px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By: /s/ Anna Gluskin</p> <p style="FONT-SIZE:13pt; CLEAR:left; MARGIN:0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Title: Chairman and Chief Executive Officer</p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br></p> <p style=MARGIN:0px><br><br></p></div></body>
<!-- EDGAR Validation Code: 432EEB0B -->
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "eastgatebiotech8-k._9.13.19.htm", "description": "8K EASTGATE BIOTECH - 09.04.19", "secsgml_size_bytes": 7355}]
{"company-data": {"conformed-name": "EASTGATE BIOTECH CORP", "cik": "0001099574", "assigned-sic": "6799", "irs-number": "870639378", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-52886", "film-number": "191094024"}, "business-address": {"street1": "2681 EAST PARLEYS WAY - SUITE 204", "city": "SALT LAKE CITY", "state": "UT", "zip": "84109", "phone": "8013223401"}, "mail-address": {"street1": "2681 EAST PARLEYS WAY - SUITE 204", "city": "SALT LAKE CITY", "state": "UT", "zip": "84109"}, "former-company": {"former-conformed-name": "EASTGATE ACQUISITIONS CORP", "date-changed": "19991123"}}
8K Eastgate Biotech - 09.04.19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
September 4, 2019
Commission File Number:
00052886
EASTGATE BIOTECH CORP.
(Exact name of small business issuer as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
87-0639378
(IRS Employer Identification No.)
2203-65 Harbour Square | Toronto, Ontario | Canada M5J 2L4
(Address of principal executive offices)
(647) 692-0652
(Registrant's Telephone number)
__________________________
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers;
On September 4, 2019, the Company announced the appointment of Bill Abajian as Chief Operating Officer.  The details of his appointment are outlined in the press release attached hereto as Exhibit 10.1 originally released on September 4, 2019.
Item 9.01  Exhibits.
(d) Exhibits.
10.1  Press Release of September 4, 2019
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EastGate Biotech Corp.
(Registrant)
Date:  September 13, 2019
By: /s/ Anna Gluskin
Title: Chairman and Chief Executive Officer